Urticaria Follow Up

Monitoring

Patients should be assessed for disease activity, impact, and control at every follow-up visit using validated patient-reported outcome measures (PROMs) (eg UAS, UAS7, AAS, CU-Q2oL, AE-QoL, UCT, AECT). Recommended tools to monitor disease activity in patients with chronic spontaneous urticaria:

• Patients with angioedema, with or without wheals: AAS
• Patients with wheals and angioedema: Both UAS7 and AAS

Recommended tools to assess disease control based on symptoms:

• Patients with wheals, with or without angioedema: UCT; CU-Q2oL may also be used
• Patients with angioedema, with or without wheals: AECT; AE-QoL may also be used
• Patients with wheals and angioedema: Both UCT and AECT; CU-Q2oL and AE-QoL may also be used

Disease Control of Chronic Urticaria  

Complete Control  

It is the absence of signs or symptoms of the disease during treatment.  

PROMs: 

• UAS7 = 0
• UCT = 16
• Angioedema absent (AAS7/8 = 0)
• Optimal quality of life (dermatology life quality index [DLQI] = 0-1)

Good Control  

There is a decrease in symptoms or signs during treatment at an appropriate level as concluded by both the physician and the patient.  

PROMs: 

• UAS7 = 1-6
• UCT = ≥12
• Angioedema present (AAS7/8 = >0)
• Good quality of life (DLQI = 2-5)

Partial Control  

There is a decrease in the intensity of the symptoms or signs while treatment is ongoing, but an adequate level has not been achieved yet based on the physician’s and the patient's assessment, and normal quality of life has not been achieved yet.  

PROMs: 

• UAS7 = >6
• UCT = <12
• Angioedema present (AAS7/8 = >0)
• With significant impact on quality of life (DLQI = >5)

Absence of Control  

It is the absence of evident positive changes in the symptoms and quality of life of the patient after treatment initiation.